Trial Search Results

B-Receptor Signaling in Cardiomyopathy

We hope to determine the importance of different genes (including B receptors) in anthracycline-induced cardiomyopathy. This has important benefits to patients exposed to anthracyclines, as this could help determine whether certain individuals have increased susceptibility to cardiac injury.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Daniel Bernstein

Stanford Investigator(s):

Eligibility


Inclusion Criteria:1.) Past exposure to anthracycline chemotherapy for cancer

2.) Echocardiogram at least six months after exposure to anthracyclines (in patients over
the age of 40, the echocardiogram must be obtained within 6 - 48 months of anthracycline
exposure)

3.) Ability to understand and the willingness to sign a written informed consent document.

We have no age, gender, or ethnic background limitations. Due to the increased frequency of
cardiovascular disease from other causes in adults over 40 years, we will limit enrollment
to those patients with an echocardiogram 6 - 48 months after the completion of
anthracycline exposure. Children will be included and will be eligible if they have an
echocardiogram at least 6 months after completion of anthracycline treatment..

Exclusion Criteria:1.) Congenital heart disease (other than patent foramen ovale)

2.) Pre-existing cardiomyopathy before anthracycline administration

3.) Patients with Down syndrome

4.) Patients receiving B-blocker therapy at the time of anthracycline exposure

5.) Pregnant patients (if their echocardiogram was obtained either during pregnancy or
within three months of pregnancy)

All participants will be cancer survivors. To minimize bias from post-partum
cardiomyopathy, pregnant patients will be excluded if their echocardiogram was obtained
during pregnancy or within three months of pregnancy. HIV-positive persons will not be
excluded from the study.

Of note, some patients receive a MUGA (multigated acquisition) study to evaluate left
ventricular ejection fraction. Patients who receive only a MUGA scan will NOT be included
in the study - an echocardiogram is necessary

Ages Eligible for Study

N/A - 40 Years

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Not Recruiting